Department of Radiation Oncology, Mount Sinai School of Medicine, New York, New York, United States of America.
PLoS One. 2012;7(6):e38465. doi: 10.1371/journal.pone.0038465. Epub 2012 Jun 29.
Persistence of γ-H2AX after ionizing radiation (IR) or drug therapy is a robust reporter of unrepaired DNA double strand breaks in treated cells.
DU-145 prostate cancer cells were treated with a chemical library ±IR and assayed for persistence of γ-H2AX using an automated 96-well immunocytochemistry assay at 4 hours after treatment. Hits that resulted in persistence of γ-H2AX foci were tested for effects on cell survival. The molecular targets of hits were validated by molecular, genetic and biochemical assays and in vivo activity was tested in a validated Drosophila cancer model.
We identified 2 compounds, MS0019266 and MS0017509, which markedly increased persistence of γ-H2AX, apoptosis and radiosensitization in DU-145 cells. Chemical evaluation demonstrated that both compounds exhibited structurally similar and biochemical assays confirmed that these compounds inhibit ribonucleotide reductase. DNA microarray analysis and immunoblotting demonstrates that MS0019266 significantly decreased polo-like kinase 1 gene and protein expression. MS0019266 demonstrated in vivo antitumor activity without significant whole organism toxicity.
MS0019266 and MS0017509 are promising compounds that may be candidates for further development as radiosensitizing compounds as inhibitors of ribonucleotide reductase.
电离辐射(IR)或药物治疗后γ-H2AX 的持续存在是治疗细胞中未修复的 DNA 双链断裂的有力报告者。
用化学文库对 DU-145 前列腺癌细胞进行处理±IR,并在处理后 4 小时使用自动化 96 孔免疫细胞化学测定法测定 γ-H2AX 的持续存在。导致 γ-H2AX 焦点持续存在的命中物被测试对细胞存活的影响。命中物的分子靶标通过分子、遗传和生化测定法进行验证,并在经过验证的果蝇癌症模型中测试了体内活性。
我们鉴定出 2 种化合物,MS0019266 和 MS0017509,它们显著增加了 DU-145 细胞中 γ-H2AX、细胞凋亡和放射增敏性的持续存在。化学评估表明,这两种化合物均表现出结构相似,生化测定法证实这些化合物抑制核苷酸还原酶。DNA 微阵列分析和免疫印迹表明,MS0019266 显著降低了 polo 样激酶 1 基因和蛋白的表达。MS0019266 表现出体内抗肿瘤活性,而无明显的全身毒性。
MS0019266 和 MS0017509 是有前途的化合物,可能是作为核苷酸还原酶抑制剂的放射增敏化合物的进一步开发的候选物。